# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-25-000034
Filing Date
2025-05-14
Accepted
2025-05-14 16:48:54
Documents
7
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | q12025form6-k.htm | 6-K | 22447
2 | EX-99.1 2025 FIRST QUARTER INTERIM FINANCIAL STATEMENT | ex991-interimfsmarch312025.htm | EX-99.1 | 347781
3 | EX-99.2 2025 FIRST QUARTER MD&A | ex992-q12025mda.htm | EX-99.2 | 216862
4 | EX-99.3 Q1 2025 CERTIFICATION CEO | ex993-q12025certificationx.htm | EX-99.3 | 14357
5 | EX-99.4 Q1 2025 CERTIFICATION CFO | ex994-q12025certificationx.htm | EX-99.4 | 14282
6 |  | oncolyticslogotaglinebluea.jpg | GRAPHIC | 355294
7 |  | pipelinepng.jpg | GRAPHIC | 528971
| Complete submission text file | 0001129928-25-000034.txt |  | 1784467

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 25946669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)